Drug Trial Radar · NCT05904626
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Elgan Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 5 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
Conditions
- Intestinal Malabsorption
Interventions
ELGN-2112Drug
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
PlaceboDrug
A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GATime frame: Five days from birth until 42 days
- Compare the safety of treatment with ELGN-2112 to placebo in preterm infants born IUGR infants<3rd percentile* born at 26-32 weeks GA.Time frame: Five days from birth until 42 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laniado Hospital
Netanya, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.